ArticleCNS drugs2011
Rituximab for secondary progressive multiple sclerosis: a case series.
Article in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.Annals of neurology · 2021Article
- RituximabTherapeutic advances in chronic disease · 2021Article
- B-cell-targeted therapies in relapsing forms of MS.Neurology(R) neuroimmunology & neuroinflammation · 2017Review
- Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Observational
- Monoclonal antibodies in treatment of multiple sclerosis.Clinical and experimental immunology · 2014Review
- Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Current treatment options in neurology · 2013Article
- B-cell targeting agents in the treatment of multiple sclerosis.Current treatment options in neurology · 2013Article
- Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.Clinical rheumatology · 2012Review
- B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms.Biologics : targets & therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS). OBJECTIVES AND
methodsIn this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months.
resultsDuring the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis.
conclusionRituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.